Cure Alzheimer's FUND

34 Washington St. Suite 200 Wellesley Hills, MA 02481 p: 877-CURE-ALZ (287-3259) f: 781-658-2399 e: info@curealz.org curealz.org

> Centre City Tower 650 Smithfield St. Suite 2015 Pittsburgh, PA 15222 p: 412-261-2785

Mission

Fund research with the highest probability of preventing, slowing or reversing Alzheimer's disease.

Board of Directors

Henry F. McCance* Lake Wales, Fla., Co-Chairman

Jeffrey L. Morby* Key Largo, Fla., Co-Chairman

> Phyllis Rappaport* Stuart, Fla., Treasurer

Tim Armour Wellesley Hills, Mass., President and CEO

Robert F. Greenhill New York City

Jacqueline C. Morby* Key Largo, Fla.

> Sherry Sharp Richmond, Va.

> > *Founder

Fundraising Programs

Laurel Lyle
Vice President, Development Operations
and Fundraising Programs

CHARITY DESIGNATION

Cure Alzheimer's Fund [®] is a "doing business as" name for the Alzheimer's Disease Research Foundation, a 501(c)(3) public charity with federal tax ID #52-2396428.

Contributing Writer: Patty Bovie Copy Editor: Colleen O'Neill Design: Winking Fish

Financial Update

	This Quarter	YTD	Inception to Date
Fundraising	\$2.3M	\$7.8M	\$ 83.5M
Expenses paid for by the board	\$0.7M	\$2.4M	\$17.5M
Funded research	\$1.4M	\$6.1M	\$57.5M

Numbers shown are preliminary for the period and are rounded to the nearest \$100,000.

Research Update (Research approved for funding during the third quarter of 2017)

Project/Researcher	Distribution Amount
Inhibition of Tau Pathology in Human Neurons — Benjamin Wolozin, M.D., Ph.D, Boston University	\$100,000
Analytical and Statistical Tools for Sequence Analysis for Alzheimer's Disease – Christoph Lange, Ph.D., Harvard School of Public Health	\$250,000
A 3-D Human Neural Cell Culture System for Studying Neuron-Microglia Interaction in Alzheimer's Disease – Hansang Cho, Ph.D., UNC Charlotte	\$2,350
Early Role of Microglia in Synapse Loss in Alzheimer's Disease – Beth Stevens, Ph.D., Boston Children's Hospital	\$150,000
Activation of the 26S Proteasome for the Treatment of Alzheimer's Disease – Alfred Goldberg, Ph.D. Harvard Medical School	\$150,000
The Role of Meningeal Lymphatics in Cleansing the Brain: Implications for Alzheimer's Disease – Jonathan Kipnis, Ph.D., University of Virginia	\$150,000
Will Restoration of Normal Glymphatic Function Slow Progression of Cognitive Decline and Amylo Plaques in a Murine Alzheimer Model? – Maiken Nedergaard, M.D., D.M.Sc., University of Rochester	\$150,000
Nanobodies to Cross the Blood-Brain Barrier – Bart De Strooper, M.D., Ph.D., and Maarten Dewilde, Ph Vlaams Instituut voor Biotechnologie	.D., \$150,000
Microglial TAM Receptors as Modulators of Alzheimer's Pathology – Greg Lemke, Ph.D., Salk Institut	te \$150,000
Evaluation of Sleep and EEG in Transgenic Mice for Vassar G2T™ Project – Psychogenics	\$55,000
G2T™ Research Models and Materials – Taconic Biosciences	\$324,780
Total Approved Research for Q3 2017	\$1,632,130

For full abstracts of all funded projects, visit curealz.org/research/funded-research.

'Tis the Season to Give

Even a small gift can make a big difference to Alzheimer's research, and giving has never been easier.

You can donate directly from our website at curealz.org, text the word RESEARCH to 41444 to send a donation, or write a check made out to Cure Alzheimer's Fund and send it via snail mail.

For gifts of securities or direct wire transfers, please contact Laurel Lyle at (781) 237-3800 for further information.

All donations are fully tax deductible. Thank you for your support!